ArticleTranslational medicine @ UniSa2024
Clinical Utility of TRBC1 Addition in Multiparametric Flow Cytometry for T Cell Lymphoma Diagnosis.
Article in Translational medicine @ UniSa, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diagnosis of T cell lymphoproliferative disorders requires one or multiple immunophenotypic aberrations, histological tissue structure or composition modifications, and T cell clonality demonstration. Here, we present two T cell lymphoma cases, where TCR clonality was evaluated using the TRBC1 monoclonal antibody combined with a multi-parametric staining for an in-depth immunophenotype of physiological and pathological T cell populations. In the first case, this monoclonal antibody allowed exclusion of reactive lymphoproliferations, while in the second case, it was conclusive for identification of Sezary syndrome cells. We added evidence on clinical utility of TRBC1 antibody (JOVI-1) to disclose monotypic T-cell populations, and TCR clonality evaluated by TRBC1 monoclonal antibody can be efficiently combined with a multi-parametric staining for an in-depth immunophenotype, with high versability of this monoclonal antibody in multi-parametric flow cytometry panel.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.